160 related articles for article (PubMed ID: 34075760)
21. Utilities of
Guan H; Toraldo G; Cerda S; Godley FA; Rao SR; McAneny D; Doherty G; Braverman L; Lee SL
Thyroid; 2020 Apr; 30(4):536-547. PubMed ID: 31996097
[No Abstract] [Full Text] [Related]
22. Molecular testing for indeterminate thyroid nodules: Performance of the Afirma gene expression classifier and ThyroSeq panel.
Jug RC; Datto MB; Jiang XS
Cancer Cytopathol; 2018 Jul; 126(7):471-480. PubMed ID: 29637728
[TBL] [Abstract][Full Text] [Related]
23. ThyroSeq overview on indeterminate thyroid nodules: An institutional experience.
Sirotnikov S; Griffith CC; Lubin D; Zhang C; Saba NF; Li D; Kornfield A; Chen A; Shi Q
Diagn Cytopathol; 2024 Jul; 52(7):353-361. PubMed ID: 38554032
[TBL] [Abstract][Full Text] [Related]
24. Mutation profiles of follicular thyroid tumors by targeted sequencing.
Duan H; Liu X; Ren X; Zhang H; Wu H; Liang Z
Diagn Pathol; 2019 May; 14(1):39. PubMed ID: 31077238
[TBL] [Abstract][Full Text] [Related]
25. UTILITY OF AFIRMA GENE EXPRESSION CLASSIFIER FOR EVALUATION OF INDETERMINATE THYROID NODULES AND CORRELATION WITH ULTRASOUND RISK ASSESSMENT: SINGLE INSTITUTIONAL EXPERIENCE.
Sultan R; Levy S; Sulanc E; Honasoge M; Rao SD
Endocr Pract; 2020 May; 26(5):543-551. PubMed ID: 31968199
[No Abstract] [Full Text] [Related]
26. Absence of EIF1AX, PPM1D, and CHEK2 mutations reported in Thyroid Cancer Genome Atlas (TCGA) in a large series of thyroid cancer.
Alzahrani AS; Murugan AK; Qasem E; Alswailem MM; AlGhamdi B; Moria Y; Al-Hindi H
Endocrine; 2019 Jan; 63(1):94-100. PubMed ID: 30269267
[TBL] [Abstract][Full Text] [Related]
27. Combined molecular and histologic end points inform cancer risk estimates for thyroid nodules classified as atypia of undetermined significance.
Onken AM; VanderLaan PA; Hennessey JV; Hartzband P; Nishino M
Cancer Cytopathol; 2021 Dec; 129(12):947-955. PubMed ID: 34314102
[TBL] [Abstract][Full Text] [Related]
28. Cytological features and nuclear scores: Diagnostic tools in preoperative fine needle aspiration of indeterminate thyroid nodules with RAS or BRAF K601E mutations?
Ravella L; Lopez J; Descotes F; Giai J; Lapras V; Denier ML; Borson-Chazot F; Lifante JC; Decaussin-Petrucci M
Cytopathology; 2021 Jan; 32(1):37-44. PubMed ID: 32803788
[TBL] [Abstract][Full Text] [Related]
29. EIF1AX c.338-2A>T splice site mutation in a patient with trabecular adenoma and cytological indeterminate lesion.
Castagna MG; Pilli T; Maino F; Marzocchi C; Cairano GD; Cantara S
Arch Endocrinol Metab; 2020 Apr; 64(2):185-189. PubMed ID: 32236306
[TBL] [Abstract][Full Text] [Related]
30. Targeted Next Generation Sequencing with ThyroSeq v2.1 for Indeterminate Thyroid Nodules in Clinical Practice.
Witt RL
Del Med J; 2016 Dec; 88(12):366-372. PubMed ID: 29461717
[TBL] [Abstract][Full Text] [Related]
31. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features in the pediatric age group.
Rossi ED; Mehrotra S; Kilic AI; Toslak IE; Lim-Dunham J; Martini M; Fadda G; Lombardi CP; Larocca LM; Barkan GA
Cancer Cytopathol; 2018 Jan; 126(1):27-35. PubMed ID: 29024469
[TBL] [Abstract][Full Text] [Related]
32. EIF1AX Mutation in a Patient with Hürthle Cell Carcinoma.
Topf MC; Wang ZX; Furlong K; Miller JL; Tuluc M; Pribitkin EA
Endocr Pathol; 2018 Mar; 29(1):27-29. PubMed ID: 28965201
[TBL] [Abstract][Full Text] [Related]
33. Thyroid nodules with KRAS mutations are different from nodules with NRAS and HRAS mutations with regard to cytopathologic and histopathologic outcome characteristics.
Radkay LA; Chiosea SI; Seethala RR; Hodak SP; LeBeau SO; Yip L; McCoy KL; Carty SE; Schoedel KE; Nikiforova MN; Nikiforov YE; Ohori NP
Cancer Cytopathol; 2014 Dec; 122(12):873-82. PubMed ID: 25132659
[TBL] [Abstract][Full Text] [Related]
34. American College of Radiology thyroid imaging report and data system combined with K-RAS mutation improves the management of cytologically indeterminate thyroid nodules.
Wu H; Zhang B; Cai G; Li J; Gu X
PLoS One; 2019; 14(7):e0219383. PubMed ID: 31295281
[TBL] [Abstract][Full Text] [Related]
35. Cytological Diagnoses Associated with Noninvasive Follicular Thyroid Neoplasms with Papillary-Like Nuclear Features According to the Bethesda System for Reporting Thyroid Cytopathology: A Systematic Review and Meta-Analysis.
Bongiovanni M; Giovanella L; Romanelli F; Trimboli P
Thyroid; 2019 Feb; 29(2):222-228. PubMed ID: 30426887
[TBL] [Abstract][Full Text] [Related]
36. The Significance of RAS-Like Mutations and MicroRNA Profiling in Predicting Malignancy in Thyroid Biopsy Specimens.
Cipriani NA; Johnson DN; Sarne DH; Angelos P; Reeves W; Antic T
Endocr Pathol; 2022 Dec; 33(4):446-456. PubMed ID: 36227454
[TBL] [Abstract][Full Text] [Related]
37. A thyroid EIF1AX story: how clinical, cytologic, and molecular surveillance led to appropriate management.
Geisler DL; Karslioglu French E; Yip L; Nikiforova MN; Nikiforov YE; Schoedel KE; Seethala RR; Ohori NP
J Am Soc Cytopathol; 2023; 12(2):105-111. PubMed ID: 36504010
[TBL] [Abstract][Full Text] [Related]
38. High risk of malignancy in cases with atypia of undetermined significance on fine needle aspiration of thyroid nodules even after exclusion of NIFTP.
Özkara SK; Bayrak BY; Turan G
Diagn Cytopathol; 2020 Nov; 48(11):986-997. PubMed ID: 32745375
[TBL] [Abstract][Full Text] [Related]
39. ROLE OF MOLECULAR MARKERS IN THYROID NODULE MANAGEMENT: THEN AND NOW.
Nikiforov YE
Endocr Pract; 2017 Aug; 23(8):979-988. PubMed ID: 28534687
[TBL] [Abstract][Full Text] [Related]
40. Effect of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP) on Malignancy Rates in Thyroid Nodules: How to Counsel Patients on Extent of Surgery.
Lindeman BM; Nehs MA; Angell TE; Alexander EK; Gawande AA; Moore FD; Doherty GM; Cho NL
Ann Surg Oncol; 2019 Jan; 26(1):93-97. PubMed ID: 30341576
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
